Aimed Bio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Aimed Bio develops next-generation cancer drugs known as antibody-drug conjugates (ADCs), engineered molecules that use an antibody to deliver a toxic payload directly to cancer cells, aiming to improve effectiveness while reducing the side effects of conventional chemotherapy.
The company licenses its drug candidates to global pharmaceutical partners rather than commercialising them independently. Listed on KOSDAQ, South Korea's tech-focused stock exchange, it operates an in-house platform that screens antibodies using patient-derived cancer cells and validates candidates in patient-derived tumour models before advancing them to clinical development.
Summary is AI-generated and may contain errors · figures from DART filings
Aimed Bio was spun off from Samsung Seoul Hospital, giving it direct access to clinical expertise and patient-derived research materials from its founding.
Aimed Bio in five facts
What does Aimed Bio do?
Aimed Bio develops next-generation cancer drugs known as antibody-drug conjugates (ADCs), engineered molecules that use an antibody to deliver a toxic payload directly to cancer cells, aiming to improve effectiveness while reducing the side effects of conventional chemotherapy.
Where is Aimed Bio listed and in which sector?
Aimed Bio (Korean name: 에임드바이오) trades under KRX code 0009K0 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is Aimed Bio?
Its market capitalisation was US$1.1B on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Aimed Bio's latest annual revenue and operating profit?
For fiscal year 2025, Aimed Bio reported revenue of US$35.7M, operating profit of US$15.7M and net income of US$3.8M, per its annual report on DART (data retrieved from DART on 2026-10-02).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] DisclosureSep 22
- Report on securities held by executives/major shareholdersSep 18
- [Amended] DisclosureSep 2
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Aimed Bio reported consolidated results for FY2025: revenue of US$32.1M (+302% year on year), operating profit of US$14M (from a loss a year earlier) and net income of US$2.88M (from a loss a year earlier).
Earnings · Feb 6 - Operating results (consolidated) (preliminary) (fair disclosure)
Aimed Bio filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$25.8M (+233% year on year), operating profit of US$17.2M (+200.1% year on year) and net income of US$23.2K (+377.9% year on year).
Earnings · Feb 6